16 results
8-K
EX-99.2
GOSS
Gossamer Bio Inc
14 May 19
Gossamer Bio Announces First Quarter 2019 Financial Results
7:31am
to deliver innovative, patient-focused new medicines for underserved therapeutic areas 4 assets in clinical development, targeting various indications … preclinical targets for future development Our People: Deeply experienced leadership team with proven track record of developing innovative clinical
8-K
EX-99.1
GOSS
Gossamer Bio Inc
6 May 24
Entry into a Material Definitive Agreement
7:31am
that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s
10-K
2018 FY
GOSS
Gossamer Bio Inc
22 Mar 19
Annual report
4:45pm
as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required … , to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drugs.
Some
DRS
z20z6x
11 Oct 18
Draft registration statement
12:00am
424B4
qcp4a acme191
8 Feb 19
Prospectus supplement with pricing info
4:40pm
S-1
x7dkwrm0g44t 8i
21 Dec 18
IPO registration
4:39pm
S-1/A
plk7gjw5q31qe exjl3i
23 Jan 19
IPO registration (amended)
4:39pm
DRS/A
owee9t6
29 Nov 18
Draft registration statement (amended)
12:00am
DEF 14A
p9qiv108 img
30 Apr 19
Definitive proxy
4:04pm
- Prev
- 1
- Next